{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T12:46:55Z","timestamp":1722689215917},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,11,12]],"date-time":"2001-11-12T00:00:00Z","timestamp":1005523200000},"content-version":"vor","delay-in-days":195,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The importance of plasma protein binding of intravenous furosemide in circulating blood for its urinary excretion and hence its diuretic effects in mutant Nagase analbuminemic rats was reported. Based on the furosemide report, the diuretic effects of another loop diuretic, bumetanide, could be expected in analbuminemic rats if plasma protein binding of bumetanide is considerable in the rats. This was proved by this study. After intravenous administration of bumetanide, 10 mg\/kg, to analbuminemic rats, the plasma protein binding of bumetanide was 36.8% in the rats mainly due to considerable binding to <jats:italic>\u03b1<\/jats:italic>\u2010 and <jats:italic>\u03b2<\/jats:italic>\u2010globulins (this value, 36.8%, was considerably greater than only 12% for furosemide), and hence the percentages of intravenous dose of bumetanide excreted in 6 h urine as unchanged drug was 16.0% in the rat (this value was considerably greater than only 7% for furosemide). After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration\u2013time curve from time zero to time infinity (1012 compared with 2472 <jats:italic>\u03bc<\/jats:italic>g min\/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml\/min\/kg) and nonrenal clearance (8.30 compared with 3.71 ml\/min\/kg)], terminal half\u2010life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml\/min\/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 <jats:italic>\u03bc<\/jats:italic>g, due to increase in intrinsic renal excretion) was significantly greater than that in control rats. The 6 h urine output and 6 h urinary excretions of sodium, chloride and potassium were comparable between two groups of rats although the 6 h urinary excretion of bumetanide was significantly greater in analbuminemic rats. This could be explained by the following. The amount of urinary excretion of bumetanide was significantly greater in analbuminemic rats than that in control rats only between 0 and 30 min urine collection. In both groups of rats, the urinary excretion rates of bumetanide during 0\u201330 min reached a upper plateau with respect to urine flow rate as well urinary excretion rates of sodium, potassium and chloride, therefore, the diuretic effects (6 h urine output and 6 h urinary excretions of sodium, potassium and chloride) were not significantly different between two groups of rats. Copyright \u00a9 2001 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.267","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T16:22:28Z","timestamp":1030292548000},"page":"147-156","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects"],"prefix":"10.1002","volume":"22","author":[{"given":"Eun J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,11,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(77)90261-8"},{"key":"e_1_2_1_3_2","volume-title":"Comprehensive Product Information","author":"Bumex\u00ae (bumetanide\/Roche)","year":"1983"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.192"},{"key":"e_1_2_1_5_2","first-page":"484","article-title":"Renal secretion of phenolsulphonphthalein: Analysis of its vectorial transport in normal and mutant analbuminemic rats","volume":"105","author":"Inoue M","year":"1985","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1985.tb09007.x"},{"key":"e_1_2_1_7_2","first-page":"1","article-title":"Pharmacokinetics of drugs in blood VI: Unusual distribution and storage effect of bumetanide","volume":"13","author":"Chang HW","year":"1988","journal-title":"Seoul Univ J Pharm Sci"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510120408"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600840224"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1991.tb00337.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600730617"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710316"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061772"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600690125"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600680843"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061729"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1538\/expanim1978.29.1_33"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018943613122"},{"key":"e_1_2_1_20_2","first-page":"255","article-title":"Arterial and venous blood sampling in pharmacokinetic studies: Bumetanide in rabbits","volume":"98","author":"Chung SY","year":"1997","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"e_1_2_1_21_2","first-page":"67","volume-title":"Clinical Bochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans","author":"Mitruka BM","year":"1981"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02353407"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510140609"},{"key":"e_1_2_1_24_2","first-page":"169","article-title":"Identification of the urinary metabolites of 14C\u2010bumetanide in the rat and their excretion by rats and dogs","volume":"4","author":"Kolis SJ","year":"1976","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.451621"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00018.x"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.267","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:12:08Z","timestamp":1700320328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1002\/bdd.267"],"URL":"https:\/\/doi.org\/10.1002\/bdd.267","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}